Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms
暂无分享,去创建一个
S. Sykes | J. Di Paola | K. Ashworth | S. Oh | A. D’Alessandro | Daniel A. C. Fisher | Tim Kong | M. Fulbright | N. Lasky | Alice Liu | Layow Yu | Fan He | A. Laranjeira | Maggie J. Cox | L. A. Heck | Angelo D’Alessandro | Angelo B A Laranjeira | LaYow Yu | Angelo B. A. Laranjeira | Maggie J Cox
[1] G. Ayers,et al. PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in patients with Myelofibrosis. , 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.
[2] T. Barbui,et al. Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment , 2022, Research and practice in thrombosis and haemostasis.
[3] J. Marinković,et al. Correlation between leukocyte‐platelet aggregates and thrombosis in myeloproliferative neoplasms , 2021, International journal of laboratory hematology.
[4] S. Bhattacharyya,et al. α-Ketoglutarate Inhibits Thrombosis and Inflammation by Prolyl Hydroxylase-2 Mediated Inactivation of Phospho-Akt , 2021, EBioMedicine.
[5] G. Challen,et al. Pevonedistat targets malignant cells in myeloproliferative neoplasms in vitro and in vivo via NFκB pathway inhibition , 2021, Blood advances.
[6] J. Zehnder,et al. Platelet transcriptome identifies progressive markers and potential therapeutic targets in chronic myeloproliferative neoplasms , 2021, Cell reports. Medicine.
[7] Jared S. Fowles,et al. DUSP6 mediates resistance to JAK2 inhibition and drives leukemic progression , 2021, bioRxiv.
[8] Jared S. Fowles,et al. Inflammatory Pathophysiology as a Contributor to Myeloproliferative Neoplasms , 2021, Frontiers in Immunology.
[9] A. Kelleher,et al. The Role of ZEB2 in Human CD8 T Lymphocytes: Clinical and Cellular Immune Profiling in Mowat–Wilson Syndrome , 2021, International Journal of Molecular Sciences.
[10] M. Elvers,et al. The pathobiology of thrombosis, microvascular disease, and hemorrhage in the myeloproliferative neoplasms. , 2021, Blood.
[11] M. Vitale,et al. Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants , 2020, Cells.
[12] Kenneth L. Jones,et al. ETV6 germline mutations cause HDAC3/NCOR2 mislocalization and upregulation of interferon response genes , 2020, JCI insight.
[13] G. Lippi,et al. Platelets Promote Thromboinflammation in SARS-CoV-2 Pneumonia , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[14] Á. Vicente,et al. Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia , 2020, Frontiers in Immunology.
[15] Kimberly A. Thomas,et al. Metabolic phenotypes of standard and cold‐stored platelets , 2019, Transfusion.
[16] Chen-Yu Liao,et al. Alpha-ketoglutarate, an endogenous metabolite, extends lifespan and compresses morbidity in aging mice , 2019, bioRxiv.
[17] M. Gassmann,et al. JAK2 mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. , 2019, Blood.
[18] Robert A. Campbell,et al. TNF-alpha driven inflammation and mitochondrial dysfunction define the platelet hyperreactivity of aging. , 2019, Blood.
[19] P. Heller,et al. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms , 2019, Front. Immunol..
[20] Jiandong Chen,et al. Interaction between p53 N terminus and core domain regulates specific and nonspecific DNA binding , 2019, Proceedings of the National Academy of Sciences.
[21] N. Siritanaratkul,et al. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms , 2019, BMC Cancer.
[22] E. Engle,et al. Cytokine production in myelofibrosis exhibits differential responsiveness to JAK-STAT, MAP kinase, and NFκB signaling , 2019, Leukemia.
[23] A. D’Alessandro,et al. High-Throughput Metabolomics: Isocratic and Gradient Mass Spectrometry-Based Methods. , 2019, Methods in molecular biology.
[24] J. Sáez-Rodríguez,et al. Benchmark and integration of resources for the estimation of human transcription factor activities , 2018, bioRxiv.
[25] T. Barbui,et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion , 2018, Blood Cancer Journal.
[26] J. Teruya-Feldstein,et al. JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition , 2018, The Journal of clinical investigation.
[27] R. Xie,et al. Platelet mitochondrial dysfunction and the correlation with human diseases. , 2017, Biochemical Society transactions.
[28] T. Weichhart,et al. mTORC1 and mTORC2 as regulators of cell metabolism in immunity , 2017, FEBS letters.
[29] G. Pinkus,et al. GATA1 Is a Sensitive and Specific Nuclear Marker for Erythroid and Megakaryocytic Lineages , 2017, American journal of clinical pathology.
[30] M. Gladwin,et al. Platelets from pulmonary hypertension patients show increased mitochondrial reserve capacity. , 2017, JCI insight.
[31] G. Nolan,et al. Mass Cytometry Analysis Reveals Hyperactive NF Kappa B Signaling in Myelofibrosis and Secondary Acute Myeloid Leukemia , 2016, Leukemia.
[32] W. Miller,et al. Megakaryocyte Polyploidization and Proplatelet Formation in Low-Attachment Conditions. , 2016, Biochemical engineering journal.
[33] S. Zucker,et al. Targeting glutamine metabolism in myeloproliferative neoplasms. , 2015, Blood cells, molecules & diseases.
[34] J. Mesirov,et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.
[35] W. Vainchenker,et al. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm. , 2014, Blood.
[36] P. Guglielmelli,et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. , 2014, Blood.
[37] Sunia,et al. The metabolite alpha-ketoglutarate extends lifespan by inhibiting the ATP synthase and TOR , 2014 .
[38] A. Green,et al. JAK2V617F leads to intrinsic changes in platelet formation and reactivity in a knock-in mouse model of essential thrombocythemia. , 2013, Blood.
[39] S. Tamura,et al. The basis examination of leukocyte–platelet aggregates with CD45 gating as a novel platelet activation marker , 2013, International journal of laboratory hematology.
[40] Qiang Wen,et al. AKT is a therapeutic target in myeloproliferative neoplasms , 2013, Leukemia.
[41] N. Jing,et al. Signal Transducer and Activator of Transcription 3 (STAT3) Regulates Collagen-Induced Platelet Aggregation Independently of Its Transcription Factor Activity , 2013, Circulation.
[42] S. Sultana,et al. Ameliorative potential of alpha-ketoglutaric acid (AKG) on acute lung injuries induced by ammonia inhalation in rats , 2012, Experimental lung research.
[43] T. Barbui,et al. Platelet‐induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera , 2011, American journal of hematology.
[44] V. Ugo,et al. Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms. , 2010, Thrombosis research.
[45] T. Barbui,et al. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms , 2010, Thrombosis and Haemostasis.
[46] Jun Xu,et al. Oligomycin-induced Bioenergetic Adaptation in Cancer Cells with Heterogeneous Bioenergetic Organization , 2010, The Journal of Biological Chemistry.
[47] V. Appanna,et al. α-Ketoglutarate Dehydrogenase and Glutamate Dehydrogenase Work in Tandem To Modulate the Antioxidant α-Ketoglutarate during Oxidative Stress in Pseudomonas fluorescens , 2009, Journal of bacteriology.
[48] P. Flevaris,et al. Two distinct roles of mitogen-activated protein kinases in platelets and a novel Rac1-MAPK-dependent integrin outside-in retractile signaling pathway. , 2009, Blood.
[49] A. Falanga,et al. Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia , 2008, Haematologica.
[50] N. Villamor,et al. Increased platelet, leukocyte, and coagulation activation in primary myelofibrosis , 2008, Annals of Hematology.
[51] M. Weiss,et al. STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice. , 2007, The Journal of clinical investigation.
[52] I. Ford,et al. Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies , 2007, Journal of thrombosis and haemostasis : JTH.
[53] N. Villamor,et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. , 2006, Haematologica.
[54] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[55] P. Perrotta,et al. Platelets express steroidogenic 17beta-hydroxysteroid dehydrogenases. Distinct profiles predict the essential thrombocythemic phenotype. , 2005, Thrombosis and haemostasis.
[56] T. Barbui,et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. , 2005, Experimental hematology.
[57] N. Hay,et al. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. , 2004, Blood.
[58] M. Jensen,et al. Increased circulating platelet–leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count , 2001, European journal of haematology.